FDA Approves Symbravo, a Combination NSAID/Triptan Therapy for Migraine Relief

New Option for Migraine Sufferers

Feb 03, 2025

∙ Paid

A futuristic medical illustration of a migraine treatment concept. The image shows a detailed neural pathway highlighted with a glowing effect, representing the targeted action of a new migraine medication. A digital overlay showcases a pill dissolving, releasing molecules that interact with nerves in the brain. The background is a scientific setting with abstract medical charts and a subtle blue gradient, conveying innovation and relief.

The FDA has approved Symbravo, a novel combination of rizatriptan (a triptan) and meloxicam (a nonsteroidal anti-inflammatory drug), developed by Axsome Therapeutics, for the acute treatment of migraine with or without aura in adults. This approval offers a new hope for patients who experience inadequate relief from currently available migraine medicati…

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.